Carbamazepine-10,11 Epoxide

Carbamazepine-10,11 Epoxide testing is used for therapeutic drug monitoring in patients treated with carbamazepine. Measuring the CBZ epoxide (carbamazepine 10,11-epoxide) concentration, interpreted with the parent-drug level, supports initial dose selection and ongoing adjustment, identifies subtherapeutic or excessive exposure, and evaluates the effects of interacting medications.

Carbamazepine is an anticonvulsant and mood-stabilizing medication used in epilepsy, bipolar disorder, and selected neuropathic pain conditions such as trigeminal neuralgia. Its actions include inhibition of voltage-gated sodium channels in hyperexcitable neurons, modulation of excitatory amino acid neurotransmission, enhancement of inhibitory GABAergic signaling, and additional effects at central adenosine receptors. Absorption is slow but extensive. Approximately 70%–80% of the drug is protein bound, and it distributes into saliva, cerebrospinal fluid, breast milk, and across the placenta. Hepatic metabolism produces several metabolites, notably carbamazepine-10,11-epoxide, which contributes to both therapeutic effect and toxicity. During chronic therapy, autoinduction shortens the elimination half-life. Adverse effects span neurologic and visual disturbances, hepatic dysfunction, hematologic abnormalities, hyponatremia, and severe cutaneous reactions. Because the therapeutic window is narrow and pharmacokinetics are altered by autoinduction and drug interactions, measuring both the parent drug and the carbamazepine epoxide metabolite supports safe and effective therapy.